Brain diseases are elusive therapeutic targets. Neurointerventions still lack an adequate level of precision to meet a demand for personalized treatments. This is evident both at the start in animal studies, and at the clinical finish. Ti-com builds on the academic heritage of its owners. We offer an expertise in the field of precision drug delivery to the brain under image guidance. We specialize in highly clinically relevant large animal models of stroke, brain cancer and other neurological diseases. Our experimental approaches fit into the precision medicine paradigm for testing the safety and efficacy of therapeutic agents and devices.